This is a follow-up to a prior study investigating the effects of subcutaneous leptin/placebo in humans. Subjects who have previously completed the prior study can enter this open-label study. Participants will inject 10 mg/ml of leptin SC BID. The length of the study is two years and subjects will be monitored with blood tests, physical examinations, and bioelectric impedance.
Showing the most recent 10 out of 412 publications